PT-141 Providers, Compared on Price and Pharmacy Transparency
6 providers, each read directly off its own site — 1 publish no price for PT-141 at all, and only 4 name their pharmacy and state a regulatory category on the PT-141 page itself.
On this page▾
/ The board
Any paid placement on this board is marked Partner and listed first, as a disclosed commercial position — within that group, and separately within every other row, every provider is still ranked on the criteria printed on this page, never anything else (see disclosure). Full write-ups below.
“Flat price” means one all-in monthly figure with no separate membership or lab fee; any other pricing chip names the mechanic that gets in the way, or that the provider has not stated one. “Labs” is whether bloodwork is required, optional, not used, or not stated on the provider's own site. The pharmacy chip states a facility type (503A pharmacy, 503B facility) only where the provider publishes one we could cite; “Not disclosed” means we read their site and they do not say, and “Unverified” means nobody has checked this company's pharmacy sourcing yet — of the 6 providers on this board, 4 publish a facility type at all. Every provider here includes the clinician consult. Each row above shows the exact date its price was checked on that provider's own site — prices can change without notice.
Every provider read live off its own site by August 2026, ranked by the same criteria as the board above: pharmacy disclosure first, then advertised price, low to high. #1 is our top pick on those criteria — filter to see the rest a different way.
All 6, by pharmacy disclosure then price
1
Telos Rx
Telos Rx has a dedicated PT-141 page, but publishes no price there — the same honest "not published" reading `other-compounds.ts` already recorded; an attempt to independently re-confirm this pass was blocked by the site itself (HTTP 429) rather than by anything found or not found.
TR
No price is published on Telos Rx's own /pages/pt-141 page, per `other-compounds.ts`'s same-day capture. This pass could not independently re-fetch that page directly — telosrx.com returned HTTP 429 (rate-limited) on three separate attempts — so this row relies on that prior capture rather than a second independent check; recorded honestly as "Not published," not guessed at.
Telos Rx's own semaglutide page states explicitly, "Telos RX prescribes compounded [medication] through a licensed US 503A pharmacy" — naming VialsRX (Houston, TX) — the disclosure already anchoring its other rows on this site. Whether that same statement is restated on its dedicated PT-141 page could not be independently confirmed this pass due to the site's rate-limiting; not assumed either way.
Strengths
A real, dedicated PT-141 product page exists on the live site, not a buried mention
Names a specific primary pharmacy (VialsRX) with a stated regulatory category on its other compound pages
Part of an already-reviewed catalogue on this site (tirzepatide, semaglutide)
Trade-offs
No price is published anywhere on its dedicated PT-141 page, per the same-day audit this row is sourced from
This pass could not independently re-confirm the page's current content — the site returned HTTP 429 on every attempt
Synergy Rx prices PT-141 "starting at $275" — re-confirmed live this pass, the identical figure as its own NAD+ and Glutathione listings — and names the same four pharmacy partners those boards already document, though neither "503A" nor "503B" appears anywhere on its own site.
SR
Synergy Rx's own site states PT-141 "Starting at $275" — re-confirmed by an independent live fetch this same pass — the identical starting-price framing and figure it uses across its whole compound catalogue.
PT-141 ships through the same four-pharmacy network as Synergy Rx's other compounds — Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx, named on the company's site but not tied to PT-141 specifically. Its own Terms of Use say only that medications "are dispensed by independent third-party pharmacies"; neither "503A" nor "503B" appears anywhere on the site checked.
Strengths
Names four real pharmacy partners, the same network already documented across this site's other boards
A published, if floor-only, starting price — re-confirmed live this pass
Part of an already-reviewed catalogue on this site (tirzepatide, sermorelin, NAD+, Glutathione)
Trade-offs
"Starting at" pricing only — no dose-tier breakdown or ceiling is published
Neither "503A" nor "503B" appears anywhere on the site, despite naming four specific pharmacies
Its own marketing claims "FDA-approved brand-name medications and compounded... formulations" generically, without ever tying that specific claim to PT-141
RxPepsDirect names its compounding pharmacy (Optimal Balance Pharmacy) and states a regulatory category for it directly on the same page that states the price — re-confirmed live this pass — and prices PT-141 at $75 per 10mg, the lowest per-unit figure on this board.
RX
RxPepsDirect's own product page states PT-141 at a plain "$75/10mg," the same per-unit, cash-pay shape as the rest of its peptide catalogue, plus a separate $39 telehealth visit fee and $15 flat shipping charged sitewide.
PT-141 ships through the same named pharmacy as RxPepsDirect's other rows: its own product page states directly, "Optimal Balance Pharmacy, a 503A pharmacy in Texas, compounds PT-141 and ships it pre-reconstituted by FedEx overnight" — re-confirmed by an independent live fetch this same pass, which additionally found "503A Compounding Pharmacy" restated in the page's own footer trust section.
Strengths
Names its compounding pharmacy (Optimal Balance Pharmacy) and states a regulatory category for it — re-confirmed live this pass, not just carried over from the prior audit
Ships pre-reconstituted rather than as a powder a buyer has to mix themselves — a real convenience most peers on this board don't offer
A la carte, per-unit pricing rather than a recurring subscription — nothing to cancel
Trade-offs
A separate $39 telehealth visit fee and $15 shipping charge sit on top of the headline $75 figure, and recur on every reorder per its own FAQ
No bundled ongoing clinician relationship in the sense a monthly-subscription competitor offers — closer to a compounding pharmacy's direct order form
Sold as generic compounded PT-141, not the FDA-approved Vyleesi product, and not restricted to the narrow indication that product is approved for
EOS Health markets PT-141 on a dedicated men's sexual-health page, "From $135.20/mo" — re-confirmed live this pass — through the same five named pharmacies and regulatory category its NAD+ and Glutathione rows already document sitewide, though not restated on the PT-141 page itself.
EH
EOS Health's own /treatments/sexual-health-mens page states PT-141 "From $135.20 / month" — re-confirmed by an independent live fetch this same pass. This is a floor price; no dose-tier ceiling is published.
EOS Health's own Clinical & Pharmacy Partners page names five pharmacies directly — GoGoMeds, The Pharmacy Hub, Hallandale Pharmacy, Strive Compounding Pharmacy, and Greenwich Rx — and states, "EOS Health uses various 503a pharmacies to dispense medications across the U.S.," the same disclosure anchoring its NAD+ and Glutathione rows. Its dedicated PT-141 page itself, re-checked live this pass, does not restate a pharmacy name or category — only a generic "Compounded in the U.S.A." badge.
Strengths
Names five pharmacy partners directly, by name and city, with a stated regulatory category — on its sitewide Clinical & Pharmacy Partners page, the most specific pharmacy disclosure of any row on this board
A real, dedicated men's sexual-health page markets PT-141 specifically, not a buried mention
24/7 provider support included at no extra cost, per its own site
Trade-offs
"From" pricing only — no dose-tier ceiling is published
The dedicated PT-141 page itself does not restate the pharmacy name or regulatory category found on the company's separate Clinical & Pharmacy Partners page
Full state coverage is stated as an unqualified all-50 claim rather than an itemized list
YourHealthRx states, unhedged, exactly which federal regulatory category its compounding pharmacies fall under, and prices PT-141 "as low as $209/mo" — re-confirmed live this pass — though no specific pharmacy is named for it.
YO
YourHealthRx's own /compounds/pt-141/index.html page states "As low as $209/month" — re-confirmed by an independent live fetch this same pass — a floor, not a stated flat rate; no dose-tier breakdown is published.
PT-141 has its own dedicated compound page, following the same template as YourHealthRx's other products. Its compound pages state directly, unhedged, "YourHealthRx connects patients with independently licensed clinicians and partner 503A compounding pharmacies" — re-confirmed live this pass — no specific pharmacy is named by name anywhere checked.
Strengths
States a direct, unhedged regulatory-category claim on its own compound pages, re-confirmed live this pass
A real, dedicated PT-141 page, following the same consistent template as the rest of its catalogue
Telemedicine access is stated as available in all 50 states, per its own Service Availability page
Trade-offs
"As low as" pricing only — no dose-tier breakdown or ceiling is published
No specific pharmacy is named by name anywhere checked
The highest published starting price of any non-partner row on this board
Bodybuilding Health+ fronts PT-141 Injection with a "$129/mo first month" figure that steps up to $179/mo afterward — re-confirmed live this pass — the same first-month-teaser pattern already documented on its tirzepatide and Glutathione rows, and names no pharmacy anywhere on the site.
BH
Bodybuilding Health+'s own site states PT-141 Injection at "$129/mo first month, then $179/mo" — re-confirmed by an independent live fetch this same pass — a real, disclosed step-up, not a hidden one, but the true standing cost is the higher figure.
PT-141 runs through the same generic-pharmacy disclosure as Bodybuilding Health+'s other compounds. Its own site states only that medications are dispensed through a generic "partner pharmacy" and "licensed U.S. pharmacies" — re-confirmed live this pass — with neither a specific name nor "503A"/"503B" stated anywhere checked.
Strengths
Discloses both the first-month promo AND the ongoing rate on the same line — a reader can see the true standing cost without digging
A real, LegitScript-verified telehealth brand under the Bodybuilding.com umbrella
Consistent, plain pricing structure across its product line
Trade-offs
The true standing cost ($179/mo) is nearly 40% higher than the "$129" figure a reader sees first
No pharmacy is named by name anywhere on the site, and neither "503A" nor "503B" is stated
What determines a row's position is printed below, and nothing else moves it: a commercial relationship can earn a provider a disclosed, labelled placement, but it cannot change the criteria, the verified prices, or the drawbacks we print beside any row. The 3 factors below are what actually move a row up or down.
No price at all is the real finding
1 of the 6 providers here publish no price for PT-141 anywhere on their own site — not a low number, an absence, and we record it plainly as "Not published" rather than guessing at one. 4 more quote only a "starting at" or "as low as" floor, or a first-month figure that steps up later, with no full dose-tier breakdown of what a real order costs. Just a couple publish one flat, unhedged price.
Pharmacy sourcing, on the record or not
We only mark a provider's pharmacy chip with a regulatory facility category when its own site names the facility AND states that category — of the 6 providers here, 4 do. Several of the rest name specific pharmacies without ever tying them to "503A" or "503B" in the same sentence, or state a category sitewide without restating it on the PT-141 page itself — a real, checkable gap, not an oversight on our part.
How the order is set
Any paid placement is marked Partner and listed first, as a disclosed commercial position — see the disclosure below the board. Within that group, and separately within every other row, the same rule applies: sorted by whether the provider clears the pharmacy-disclosure bar above, then by their own advertised price, low to high, for rows that tie. A provider's placement within its own group is never for sale.
Before you compare prices: PT-141 (bremelanotide) is different from every other compound this site boards. Unlike NAD+ and Glutathione, it does have an FDA-approved drug product: Vyleesi (bremelanotide injection), NDA 210557, approved by FDA in 2019 and manufactured by Cosette Pharmaceuticals — confirmed live on DailyMed, August 2026. But Vyleesi's approval covers one narrow use: "treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)" — nothing broader. Every provider on this board sells generic, compounded PT-141, not Vyleesi itself, and several market it to men specifically or with no HSDD-specific framing at all — a different population and use than the one FDA actually reviewed. That is a materially different situation from this site's tirzepatide and semaglutide boards, where a compounded version is sold specifically because the FDA-approved brand is in shortage: no shortage is behind what's sold here. What we score here is how honestly and clearly each provider states its price and pharmacy sourcing — not whether compounded PT-141 is an appropriate choice for you. Talk to a licensed clinician about that part.
Only confirmed PT-141 sellers are ranked here. Looking for a related wellness compound instead? Our GHK-Cu comparison shares three providers with this roster (Bodybuilding Health+, RxPepsDirect, YourHealthRx) but is not the same list — a provider selling PT-141 does not necessarily sell GHK-Cu, and vice versa. Our NAD+ and Glutathione comparisons use the same pharmacy-first method against different longevity-compound rosters. Looking for a GLP-1 or growth-hormone-axis peptide instead? Our tirzepatide comparison and sermorelin comparison round out the rest — see each board's own roster for what it actually confirmed.
Nothing on this page is medical advice. The only FDA-approved bremelanotide product is Vyleesi, approved for a specific indication in premenopausal women; every product on this board is a compounded formulation sold under a pharmacy's general authority, not Vyleesi itself and not a medication FDA has reviewed for the safety or efficacy of the use these providers market it for. We read every price and sourcing claim on this page directly off each provider's own site by August 2026; providers change prices without telling us, so verify the current number before you buy. Ask a licensed clinician whether PT-141 fits your situation.